---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-22-000022"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T05:11:32.238107+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q4 revenue up 4% to $160.8M; GAAP EPS $(0.10), adjusted $(0.02)

## Summary
- Revenue $160.8M (+4% YoY); full-year $690.6M (+24%). Ex-divested businesses, Q4 revenue up 19%.
- GAAP diluted EPS $(0.10); adjusted EPS $(0.02); GAAP gross margin 71.5%, adjusted 71.8%.
- Hereditary cancer revenue $74.8M (-5% YoY); pharmacogenomics $29.4M (+63%); prenatal $30.1M (+43%).
- FY2022 guidance: revenue $670-700M, adjusted EPS $0.00-$0.20, adjusted gross margin 70-72%.
- Ended Q4 with $398.8M cash, no debt; Omicron variant adversely impacted hereditary cancer volumes.

## SEC filing metadata
- accession: 0000899923-22-000022
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992322000022/0000899923-22-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992322000022/mygn-20220224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-22-000022
- JSON: https://secwatch.observer/filing/0000899923-22-000022.json
- Plain text: https://secwatch.observer/filing/0000899923-22-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.